Summary

Global Incretin-Based Drugs Market was valued at USD 37.14 billion in 2023, and is anticipated to grow with a healthy growth rate of CAGR of 7.96% during the forecast period 2024-2032. Incretin-based drugs are a class of medications used to manage type 2 diabetes. These drugs mimic or enhance the effects of incretins, which are hormones that stimulate insulin release from the pancreas in response to meals. Through improving insulin secretion and reducing glucagon levels, incretin-based therapies help regulate blood sugar levels more effectively. Common types of incretin-based drugs include GLP-1 receptor agonists and DPP-4 inhibitors, both of which play a significant role in improving glycemic control and overall diabetes management.
The Global Incretin-Based Drugs Market is driven by rise in the prevalence of type 2 diabetes worldwide, coupled with an increase in the prescription of incretin-based drugs for its treatment, is driving the growth of the market. Incretin-based drugs have become essential in managing type 2 diabetes as they help regulate blood glucose levels by boosting insulin secretion and reducing glucagon release. This innovative approach to diabetes therapy addresses the escalating need for effective treatments in the face of a growing global diabetes population. The market's expansion is further fueled by significant investments in research and development of diabetes therapies that utilize incretin. Moreover, a strong pipeline of products and ongoing research are expected to drive the market forward over the forecast period. However, the market faces challenges such as side effects associated with excessive use and the high cost of incretin drugs, which may hinder widespread adoption.
The key regions considered for the Global Incretin-Based Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Asia-Pacific is poised to be the fastest-growing market for incretin-based drugs owing to rising healthcare expenditure and improving healthcare infrastructure. The increasing burden of chronic diseases including diabetes in this region underscores the demand for innovative and effective treatments, thereby expanding the market for incretin-based drugs. Furthermore, the market in North America is anticipated to dominate in terms of revenue over the forecast period 2024-2032.


Major market players included in this report are:
Sun Pharmaceutical Industries Ltd.
Lupin
Takeda Pharmaceutical Company Ltd.
AstraZeneca plc
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Novartis AG
Novo Nordisk A/S
Merck & Co., Inc
Sanofi

The detailed segments and sub-segment of the market are explained below:
By Drug Class:
• GLP-1 receptor agonists
• DPP-4 inhibitors
By Route of Administration:
• Oral
• Parenteral
By Distribution Channel:
• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers
By Region:
North America:
• U.S.
• Canada
Europe:
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific:
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America:
• Brazil
• Mexico
Middle East & Africa:
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Global Incretin-Based Drugs Market Executive Summary
1.1. Global Incretin-Based Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Route of Administration
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Incretin-Based Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Incretin-Based Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Type 2 Diabetes
3.1.2. Surge in R&D of Diabetes Therapies
3.2. Market Challenges
3.2.1. Side Effects Associated with Excessive Use
3.2.2. High Cost of Incretin Drugs High Costs
3.3. Market Opportunities
3.3.1. Increase In Pipeline of Incretin-Based Products

Chapter 4. Global Incretin-Based Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Incretin-Based Drugs Market Size & Forecasts by Drug Class 2022-2032
5.1. Segment Dashboard
5.2. Global Incretin-Based Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. GLP-1 receptor agonists
5.2.2. DPP-4 inhibitors

Chapter 6. Global Incretin-Based Drugs Market Size & Forecasts by Route of Administration 2022-2032
6.1. Segment Dashboard
6.2. Global Incretin-Based Drugs Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Parenteral

Chapter 7. Global Incretin-Based Drugs Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Segment Dashboard
7.2. Global Incretin-Based Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Hospital Pharmacies
7.2.2. Drug Stores and Retail Pharmacies
7.2.3. Online Providers

Chapter 8. Global Incretin-Based Drugs Market Size & Forecasts by Region 2022-2032
8.1. North America Incretin-Based Drugs Market
8.1.1. U.S. Incretin-Based Drugs Market
8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.1.2. Canada Incretin-Based Drugs Market
8.2. Europe Incretin-Based Drugs Market
8.2.1. U.K. Incretin-Based Drugs Market
8.2.2. Germany Incretin-Based Drugs Market
8.2.3. France Incretin-Based Drugs Market
8.2.4. Spain Incretin-Based Drugs Market
8.2.5. Italy Incretin-Based Drugs Market
8.2.6. Rest of Europe Incretin-Based Drugs Market
8.3. Asia-Pacific Incretin-Based Drugs Market
8.3.1. China Incretin-Based Drugs Market
8.3.2. India Incretin-Based Drugs Market
8.3.3. Japan Incretin-Based Drugs Market
8.3.4. Australia Incretin-Based Drugs Market
8.3.5. South Korea Incretin-Based Drugs Market
8.3.6. Rest of Asia Pacific Incretin-Based Drugs Market
8.4. Latin America Incretin-Based Drugs Market
8.4.1. Brazil Incretin-Based Drugs Market
8.4.2. Mexico Incretin-Based Drugs Market
8.4.3. Rest of Latin America Incretin-Based Drugs Market
8.5. Middle East & Africa Incretin-Based Drugs Market
8.5.1. Saudi Arabia Incretin-Based Drugs Market
8.5.2. South Africa Incretin-Based Drugs Market
8.5.3. Rest of Middle East & Africa Incretin-Based Drugs Market

Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Sun Pharmaceutical Industries Ltd.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Lupin
9.3.3. Takeda Pharmaceutical Company Ltd.
9.3.4. AstraZeneca plc
9.3.5. Boehringer Ingelheim International GmbH
9.3.6. Eli Lilly and Company
9.3.7. Novartis AG
9.3.8. Novo Nordisk A/S
9.3.9. Merck & Co., Inc
9.3.10. Sanofi

Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes